RBC Capital keeps EyePoint at Sector Perform with a $1 price target
RBC Capital maintained its Sector Perform rating on EyePoint with a $1 target after DURAVYU missed its wet AMD Phase III endpoint. Data from Benzinga via TradingView.
- published on Newsmetry
- original source published
the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner. connect the api →
what happened
RBC Capital kept its Sector Perform rating on EyePoint shares and set a price target of $1. According to TradingView, citing Benzinga data, that level implies a 127.3% upside from the October 19 close of $0.44.
Recent Phase III trials of DURAVYU in wet age-related macular degeneration failed to meet the primary endpoint of non-inferiority. The analyst lowered the target and kept a cautious stance, pointing to limited near-term upside.
Management remains confident in the diabetic macular edema (DME) program, which is on track for a readout in Q4 2027. The company also reports a solid cash position.
why it matters
For investors, the key issue is the failed wet AMD study, which hurt confidence in the shares. The stock's next direction will depend on progress in the DME program and on how the company sets its priorities. A single analyst's rating does not change the broader picture, so the update is mainly informational.
tags
instruments
sources
- RBC Capital maintains Sector Perform rating on EyePoint, $1 price target — TradingView, 20 October 2026 at 13:18 UTC
- RBC Capital reiterates Sector Perform rating on Public Storage, $318 price target — TradingView, 20 October 2026 at 13:26 UTC
- RBC Capital reiterates Sector Perform rating on Zions Bancorp, $76 price target — TradingView, 20 October 2026 at 13:35 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner.
get stories in real time ↗